Independent Data Safety Monitoring Board unanimously recommends continuation of the global Phase 2/3 study of orally-administered opaganib in severe COVID-19 pneumonia based on review of unblinded safety data from the first 255 treated patients The 464-patient global Phase 2/3 COVID-19 study is ...
TEL AVIV, Israel and RALEIGH, N.C. , March 25, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that RedHill Biopharma Inc. , AztraZeneca AB and AstraZenca Pharmaceuticals LP ("AZ") and Nektar ...
TEL AVIV, Israel and RALEIGH, N.C. , March 22, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has acted on a request to provide opaganib [1] treatment on an outpatient basis under compassionate ...
TEL AVIV, Israel and RALEIGH, N.C. , March 18, 2021 /PRNewswire/ -- Financials : Full year 2020 net revenues of approximately $64 million , with gross profit of approximately $27.5 million Solid cash balance of approximately $100 million as of March 4, 2021 Planned commercial operational ...
TEL AVIV, Israel and RALEIGH, NC , March 11, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its fourth quarter and full year 2020 financial results and operational highlights on ...
TEL AVIV, Israel and RALEIGH, NC , March 5, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will present at the following upcoming virtual conferences in March: Sachs Spring Life Sciences Week ( ...
TEL AVIV, Israel and RALEIGH, N.C. , March 4, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 4,375,000 American Depositary Shares ...
TEL AVIV, Israel and RALEIGH, NC , March 2, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that due to demand, the underwriter has agreed to increase the size of the previously announced public offering ...
TEL AVIV, Israel and RALEIGH, N.C. , March 1, 2021 /PRNewswire/ -- RedHill Biopharma Ltd . (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into an underwriting agreement with H.C. ...
Following review of data from the U.S. Phase 2 study by the FDA, RedHill plans to expand the global Phase 2/3 study of orally-administered opaganib for severe COVID-19 to the U.S. The study has enrolled over 50% of the targeted 464 patients globally; U.S. ...
Menu